This program offers loan assistance of up to $100,000 to eligible pediatric medical subspecialists in exchange for a three-year, full-time service commitment at an approved facility in an underserved area. Pediatric rheumatologists are encouraged to apply.

The Pediatric Rheumatology Workforce: Too Many Kids, Too Few Providers
“Fifty percent of kids with rheumatic disease are taken care of by adult providers,” says Jay J. Mehta, MD, MS, attending physician and fellowship program director, Department of Rheumatology, Children’s Hospital of Philadelphia, and a co-author of the ACR’s recent pediatric workforce shortage study.1,2 “But adult rheumatologists may not have specific training in the rheumatic…

Baricitinib Promising for Juvenile Idiopathic Arthritis
In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.

European Medicines Agency Committee Issues Positive Opinion for Secukinumab in Pediatric Arthritic Disease
In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.

FDA Approves Secukinumab for Children with Enthesitis-Related Arthritis & PsA
The FDA has approved the use of secukinumab for pediatric patients with enthesitis-related arthritis and psoriatic arthritis, after research showed a longer time to disease flare than placebo.

The State of Clinical Science for Pediatric Rheumatology in 2021
ACR Convergence 2021—The Pediatric Rheumatology Year in Review began with a fascinating talk by Mara Becker, MD, MSCE, a professor of Pediatrics and vice chair of faculty at Duke University School of Medicine, Durham, N.C. Dr. Becker began by describing her search strategy to select high-yield clinical science publications in pediatric rheumatology from the past…

How Pediatric Rheumatologists Are Moving Lupus Research Forward
In the 2021 Edmund L. Dubois, MD, Memorial Lectureship, Aimee Hersh, MD, discussed her work on defining research priorities in pediatric lupus.

EU Approves Tofacitinib Citrate for 2 Pediatric Conditions
The European Commission approved tofacitinib citrate to treat two pediatric conditions, as well as a prolonged-release version of the medication designed to treat adults with active PsA.
Washington Pediatric Rheumatologists Eligible for Loan Forgiveness
The 2021–23 Washington budget enables consideration of pediatric rheumatologists for state loan forgiveness programs during the 2019–21 and 2021–23 cycles, making it the first state to include any rheumatologists in its loan forgiveness programs.

Updates in Pediatric Lupus: Experts Discuss Advances in Lupus Nephritis Treatments, Monogenic Lupus & More
PRSYM—At the 2021 Pediatric Rheumatology Symposium (PRSYM), a session on lupus provided a robust discussion of recent advances in lupus treatments and genetic discoveries in pediatric rheumatology. Lupus Nephritis The first speaker was Shaun Jackson, MD, PhD, a pediatric nephrologist and rheumatologist and associate professor at Seattle Children’s. His presentation focused on state-of-the-art treatments in…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »